RE: Worth multiples fully funded15 Sep 2025 15:42
Correction.
UglyButler.
Personally I can't see Myriad Genetics not doing some sort of deal with AGL that is financially significant.
1. It is already proven that Angle's "dual analysis" finds about 50% more cancer biomarkers that CtDna alone, or tissue analysis.
- So this is a technical issue to add this to the existing tissue analysis Myriad already do, with thousands of clients.
2. Adding the analysis of CTC's would be fantastic publicity for Myriad. This alone, with the sales capability of a Company like Myriad will make a lot of money for them. Just to be able to say "including CTC analysis" is worth a fortune in itself.
All IMHO.